

Ralph N Martins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4707476/publications.pdf>

Version: 2024-02-01

387
papers

28,552
citations

11908

72
h-index

8212

153
g-index

440
all docs

440
docs citations

440
times ranked

29225
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1141-1154.	0.4	89
2	Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1754-1764.	0.4	4
3	Analysis of plasma proteins using 2D gels and novel fluorescent probes: in search of blood based biomarkers for Alzheimer's disease. <i>Proteome Science</i> , 2022, 20, 2.	0.7	6
4	APOE $\epsilon 2$ resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. <i>Alzheimer's and Dementia</i> , 2022, 18, 2151-2166.	0.4	16
5	Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 261.	4.5	15
6	Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. <i>Lancet Neurology</i> , The, 2022, 21, 140-152.	4.9	34
7	Plasma microRNA vary in association with the progression of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12251.	1.2	11
8	Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12307.	1.2	14
9	A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 780602.	1.7	7
10	Novel Amylin Analogues Reduce Amyloid- β Cross-Seeding Aggregation and Neurotoxicity. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-18.	1.2	2
11	The Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 771214.	1.7	8
12	Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF A β 242 moderates the association between insulin resistance and increased CSF tau levels. <i>Neurobiology of Aging</i> , 2022, 114, 38-48.	1.5	5
13	Validation of Plasma Amyloid- β 42/40 for Detecting Alzheimer Disease Amyloid Plaques. <i>Neurology</i> , 2022, 98, .	1.5	89
14	Differential Effects of APOE and Modifiable Risk Factors on Hippocampal Volume Loss and Memory Decline in A β ⁺ and A β ⁻ Older Adults. <i>Neurology</i> , 2022, 98, e1704-e1715.	1.5	4
15	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. <i>Biomedicine</i> , 2022, 10, 1045.	1.4	1
16	Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid- β . <i>Neurobiology of Disease</i> , 2022, 171, 105783.	2.1	5
17	Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease. <i>Nature Communications</i> , 2022, 13, .	5.8	30
18	Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults. <i>Journal of Neurochemistry</i> , 2021, 159, 389-402.	2.1	20

#	ARTICLE	IF	CITATIONS
19	Association of β -Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. <i>Neurology</i> , 2021, 96, e662-e670.	1.5	34
20	High-density lipoprotein-related cholesterol metabolism in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2021, 159, 343-377.	2.1	8
21	A Randomized Controlled Trial of High-Intensity Exercise and Executive Functioning in Cognitively Normal Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 129-140.	0.6	6
22	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 776-785.	0.7	30
23	Aggregation of Abnormal Memory Scores and Risk of Incident Alzheimer's Disease Dementia: A Measure of Objective Memory Impairment in Amnesic Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 146-157.	1.2	3
24	Flavonoid intake and incident dementia in the Danish Diet, Cancer, and Health cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12175.	1.8	7
25	Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 895-903.	1.2	5
26	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12197.	1.2	4
27	SPON1 Is Associated with Amyloid- β and APOE ϵ 4-Related Cognitive Decline in Cognitively Normal Adults. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 111-120.	1.2	5
28	High-intensity exercise and cognitive function in cognitively normal older adults: a pilot randomised clinical trial. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 33.	3.0	16
29	Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2931.	1.8	10
30	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. <i>Brain</i> , 2021, 144, 2176-2185.	3.7	66
31	Relevance of a Truncated PRESENILIN 2 Transcript to Alzheimer's Disease and Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1479-1489.	1.2	4
32	Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 79.	3.0	0
33	Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition. <i>Hormones and Behavior</i> , 2021, 131, 104966.	1.0	2
34	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 443-468.	1.2	59
35	Longitudinal Trajectories in Cortical Thickness and Volume Atrophy: Superior Cognitive Performance Does Not Protect Against Brain Atrophy in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1039-1052.	1.2	2
36	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , The, 2021, 20, 615-626.	4.9	26

#	ARTICLE	IF	CITATIONS
37	Intake of Products Containing Anthocyanins, Flavanols, and Flavanones, and Cognitive Function: A Narrative Review. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 640381.	1.7	11
38	Investigating Auditory Electrophysiological Measures of Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Event-Related Potential Studies. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 419-448.	1.2	13
39	Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 27.	2.4	207
40	Potential of Sorghum Polyphenols to Prevent and Treat Alzheimer's Disease: A Review Article. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 729949.	1.7	14
41	Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin A for Alzheimer's Disease. <i>Nutrients</i> , 2021, 13, 3744.	1.7	24
42	Sleep Mediates Age-Related Executive Function for Older Adults with Limited Cognitive Reserve. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 711-721.	1.2	10
43	Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral A β -Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 744872.	1.7	17
44	Mitoprotective Effects of a Synergistic Nutraceutical Combination: Basis for a Prevention Strategy Against Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 781468.	1.7	4
45	Influence of Comorbidity of Cerebrovascular Disease and Amyloid- β on Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 897-907.	1.2	21
46	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. <i>Brain Communications</i> , 2020, 2, fcaa102.	1.5	11
47	Systematic review protocol for assessing central auditory functions of Alzheimer's disease and its preclinical stages. <i>BMJ Open</i> , 2020, 10, e033342.	0.8	2
48	Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 5698.	5.8	76
49	Auditory electrophysiological assessments of Alzheimer's disease and preclinical stages: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e033308.	0.8	3
50	Evaluation of GammaH2AX in Buccal Cells as a Molecular Biomarker of DNA Damage in Alzheimer's Disease in the AIBL Study of Ageing. <i>Life</i> , 2020, 10, 141.	1.1	2
51	Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer's Disease Patients and Correlates with Cognitive Performance. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 733-744.	1.2	7
52	Activate or Inhibit? Implications of Autophagy Modulation as a Therapeutic Strategy for Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6739.	1.8	20
53	The Peripheral Hearing and Central Auditory Processing Skills of Individuals With Subjective Memory Complaints. <i>Frontiers in Neuroscience</i> , 2020, 14, 888.	1.4	7
54	Validation and Reliability of the Alzheimer's Disease-Commonwealth Scientific and Industrial Research Organisation Food Frequency Questionnaire. <i>Nutrients</i> , 2020, 12, 3605.	1.7	3

#	ARTICLE	IF	CITATIONS
55	Targeting Mitophagy in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1273-1297.	1.2	6
56	Relationship of Established Cardiovascular Risk Factors and Peripheral Biomarkers on Cognitive Function in Adults at Risk of Cognitive Deterioration. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 163-171.	1.2	13
57	PRKAG2 Gene Expression Is Elevated and its Protein Levels Are Associated with Increased Amyloid- β^2 Accumulation in the Alzheimer's Disease Brain. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 441-448.	1.2	8
58	Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 303-315.	1.2	23
59	Plasma transferrin and hemopexin are associated with altered $A\beta$ uptake and cognitive decline in Alzheimer's disease pathology. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 72.	3.0	19
60	Impact of APOE- ϵ 4 carriage on the onset and rates of neocortical $A\beta$ -amyloid deposition. <i>Neurobiology of Aging</i> , 2020, 95, 46-55.	1.5	32
61	Amla Therapy as a Potential Modulator of Alzheimer's Disease Risk Factors and Physiological Change. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 713-733.	1.2	3
62	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2020, 26, 398-407.	15.2	351
63	Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12005.	1.2	35
64	Amylin and beta amyloid proteins interact to form amorphous heterocomplexes with enhanced toxicity in neuronal cells. <i>Scientific Reports</i> , 2020, 10, 10356.	1.6	44
65	Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid- β^2 Load. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 291-301.	1.2	3
66	Worldwide FINGERS Network: A global approach to risk reduction and prevention of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 1078-1094.	0.4	257
67	Bilingualism Is Associated with a Delayed Onset of Dementia but Not with a Lower Risk of Developing it: a Systematic Review with Meta-Analyses. <i>Neuropsychology Review</i> , 2020, 30, 1-24.	2.5	30
68	Sex and APOE ϵ 4 genotype modify the Alzheimer's disease serum metabolome. <i>Nature Communications</i> , 2020, 11, 1148.	5.8	115
69	Potential of coconut oil and medium chain triglycerides in the prevention and treatment of Alzheimer's disease. <i>Mechanisms of Ageing and Development</i> , 2020, 186, 111209.	2.2	54
70	Autophagy modulates $A\beta$ accumulation and formation of aggregates in yeast. <i>Molecular and Cellular Neurosciences</i> , 2020, 104, 103466.	1.0	9
71	Sodium Butyrate Reduces Brain Amyloid- β^2 Levels and Improves Cognitive Memory Performance in an Alzheimer's Disease Transgenic Mouse Model at an Early Disease Stage. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 91-99.	1.2	65
72	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). <i>Alzheimer's and Dementia</i> , 2020, 16, 219-228.	0.4	13

#	ARTICLE	IF	CITATIONS
73	Personality factors and cerebral glucose metabolism in community-dwelling older adults. <i>Brain Structure and Function</i> , 2020, 225, 1511-1522.	1.2	3
74	Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 36.	3.0	39
75	Comorbidity of Cerebrovascular and Alzheimer's Disease in Aging. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 321-334.	1.2	4
76	Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-A β load and cerebrospinal fluid A β in a pilot study of Alzheimer's disease. <i>Neuroscience Letters</i> , 2020, 731, 135078.	1.0	6
77	A rapid absorbance-based growth assay to screen the toxicity of oligomer A β ₄₂ and protect against cell death in yeast. <i>Neural Regeneration Research</i> , 2020, 15, 1931.	1.6	3
78	Twelve weeks of resistance training does not influence peripheral levels of neurotrophic growth factors or homocysteine in healthy adults: a randomized-controlled trial. <i>European Journal of Applied Physiology</i> , 2019, 119, 2167-2176.	1.2	10
79	Ultrasensitive Detection of Plasma Amyloid- β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 775-783.	1.2	38
80	Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers. <i>Annals of Neurology</i> , 2019, 86, 616-625.	2.8	22
81	Resistance training enhances delayed memory in healthy middle-aged and older adults: A randomised controlled trial. <i>Journal of Science and Medicine in Sport</i> , 2019, 22, 1226-1231.	0.6	12
82	Plasma neurofilament light chain and amyloid- β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 186.	3.1	41
83	Autophagy Modulation as a Treatment of Amyloid Diseases. <i>Molecules</i> , 2019, 24, 3372.	1.7	53
84	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. <i>Nature Medicine</i> , 2019, 25, 277-283.	15.2	610
85	Klotho allele status is not associated with A β and APOE ϵ 4-related cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 76, 162-165.	1.5	23
86	Autophagy Promotes Memory Formation. <i>ACS Chemical Neuroscience</i> , 2019, 10, 3337-3339.	1.7	8
87	Effects of Testosterone Supplementation on Separate Cognitive Domains in Cognitively Healthy Older Men: A Meta-analysis of Current Randomized Clinical Trials. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 1232-1246.	0.6	26
88	COMT val158met is not associated with A β -amyloid and APOE ϵ 4 related cognitive decline in cognitively normal older adults. <i>IBRO Reports</i> , 2019, 6, 147-152.	0.3	5
89	Development of an innovative technology to segment luminal borders of intravascular ultrasound image sequences in a fully automated manner. <i>Computers in Biology and Medicine</i> , 2019, 108, 111-121.	3.9	6
90	Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid- β and tau. <i>Neurobiology of Aging</i> , 2019, 80, 11-20.	1.5	80

#	ARTICLE	IF	CITATIONS
91	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019, 5, eaau7220.	4.7	59
92	Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 1833-1863.	2.4	75
93	Higher Cardiorespiratory Fitness Is Associated With Better Verbal Generativity in Community-Dwelling Older Adults. <i>Journal of Aging and Physical Activity</i> , 2019, 27, 703-710.	0.5	3
94	Validation of a priori candidate Alzheimer's disease SNPs with brain amyloid-beta deposition. <i>Scientific Reports</i> , 2019, 9, 17069.	1.6	15
95	Sleep disruption explains age-related prospective memory deficits: implications for cognitive aging and intervention. <i>Aging, Neuropsychology, and Cognition</i> , 2019, 26, 621-636.	0.7	16
96	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimer's and Dementia</i> , 2019, 15, 292-312.	0.4	310
97	Assessment of diets containing curcumin, epigallocatechin-3-gallate, docosahexaenoic acid and α -lipoic acid on amyloid load and inflammation in a male transgenic mouse model of Alzheimer's disease: Are combinations more effective?. <i>Neurobiology of Disease</i> , 2019, 124, 505-519.	2.1	36
98	Influence of BDNF Val66Met on the relationship between cardiorespiratory fitness and memory in cognitively normal older adults. <i>Behavioural Brain Research</i> , 2019, 362, 103-108.	1.2	10
99	Modulating functional connectivity with non-invasive brain stimulation for the investigation and alleviation of age-associated declines in response inhibition: A narrative review. <i>NeuroImage</i> , 2019, 185, 490-512.	2.1	21
100	Subjective memory complaints predict baseline but not future cognitive function over three years: results from the Western Australia Memory Study. <i>International Psychogeriatrics</i> , 2019, 31, 513-525.	0.6	13
101	Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain $A\beta$ -amyloid burden. <i>Translational Psychiatry</i> , 2018, 8, 47.	2.4	92
102	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. <i>Brain</i> , 2018, 141, 1486-1500.	3.7	79
103	Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer's disease. <i>Personalized Medicine in Psychiatry</i> , 2018, 7-8, 14-20.	0.1	13
104	Association of Plasma Neurofilament Light Chain with Neocortical Amyloid- β Load and Cognitive Performance in Cognitively Normal Elderly Participants. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 479-487.	1.2	50
105	Systematic Evaluation of the Use of Human Plasma and Serum for Mass-Spectrometry-Based Shotgun Proteomics. <i>Journal of Proteome Research</i> , 2018, 17, 1426-1435.	1.8	37
106	Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1589-1598.	1.2	44
107	High performance plasma amyloid- β biomarkers for Alzheimer's disease. <i>Nature</i> , 2018, 554, 249-254.	13.7	1,180
108	KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ϵ 4-positive cognitively normal adults with high $A\beta$ -amyloid burden. <i>Scientific Reports</i> , 2018, 8, 2034.	1.6	31

#	ARTICLE	IF	CITATIONS
109	Association of β -Amyloid and Apolipoprotein E ϵ 4 With Memory Decline in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 488.	4.5	70
110	Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. <i>Journal of Affective Disorders</i> , 2018, 229, 269-274.	2.0	27
111	IMPACT OF COCHLEAR IMPLANTATION ON COGNITIVE FUNCTIONS OF OLDER ADULTS: PILOT TEST RESULTS. <i>Otology and Neurotology</i> , 2018, 39, 514-515.	0.7	47
112	Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 965-992.	1.2	96
113	Baseline Amnestic Severity Predicts Progression From Amnestic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 190-196.	0.6	19
114	Role of the cell membrane interface in modulating production and uptake of Alzheimer's beta amyloid protein. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2018, 1860, 1639-1651.	1.4	47
115	Elevated plasma ferritin in elderly individuals with high neocortical amyloid- β load. <i>Molecular Psychiatry</i> , 2018, 23, 1807-1812.	4.1	49
116	Trajectories of depressive and anxiety symptoms in older adults: a 6-year prospective cohort study. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 405-413.	1.3	20
117	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study. <i>Alzheimer's and Dementia</i> , 2018, 14, 43-53.	0.4	42
118	Physical Activity in Preventing Alzheimer's Disease and Cognitive Decline: A Narrative Review. <i>Sports Medicine</i> , 2018, 48, 29-44.	3.1	33
119	P392: HYPERSPECTRAL RETINAL IMAGING FEATURES AND ITS ASSOCIATION WITH BRAIN AMYLOID BURDEN IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1247.	0.4	0
120	A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 423.	1.7	16
121	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1427-1437.	0.4	51
122	Mediterranean diet adherence and rate of cerebral β -amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. <i>Translational Psychiatry</i> , 2018, 8, 238.	2.4	49
123	Efficient production of a mature and functional gamma secretase protease. <i>Scientific Reports</i> , 2018, 8, 12834.	1.6	5
124	Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1299-1305.	1.2	28
125	Personality characteristics are independently associated with prospective memory in the laboratory, and in daily life, among older adults. <i>Journal of Research in Personality</i> , 2018, 76, 32-37.	0.9	2
126	Impact of Aging on the Auditory System and Related Cognitive Functions: A Narrative Review. <i>Frontiers in Neuroscience</i> , 2018, 12, 125.	1.4	123

#	ARTICLE	IF	CITATIONS
127	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. <i>PLoS ONE</i> , 2018, 13, e0195838.	1.1	51
128	Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid- β load: A pilot study. <i>Scientific Reports</i> , 2018, 8, 8008.	1.6	45
129	Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer's disease, mild cognitive impairment, and healthy aging: A longitudinal study.. <i>Psychological Assessment</i> , 2018, 30, 1308-1316.	1.2	5
130	Amyloid burden and incident depressive symptoms in cognitively normal older adults. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 455-463.	1.3	49
131	Serum high-density lipoprotein is associated with better cognitive function in a cross-sectional study of aging women. <i>International Journal of Neuroscience</i> , 2017, 127, 243-252.	0.8	34
132	Enhancing Cognitive Functioning in Healthy Older Adults: a Systematic Review of the Clinical Significance of Commercially Available Computerized Cognitive Training in Preventing Cognitive Decline. <i>Neuropsychology Review</i> , 2017, 27, 62-80.	2.5	108
133	Selenium Levels in Serum, Red Blood Cells, and Cerebrospinal Fluid of Alzheimer's Disease Patients: A Report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL). <i>Journal of Alzheimer's Disease</i> , 2017, 57, 183-193.	1.2	54
134	APOE ϵ 4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 411-422.	1.2	9
135	Plasma Amyloid- β Peptides in Type 2 Diabetes: A Matched Case-Control Study. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1127-1133.	1.2	14
136	Alterations in erythrocyte fatty acid composition in preclinical Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 676.	1.6	35
137	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1197-1206.	0.4	45
138	Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 60-72.	1.2	29
139	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 1225.	1.6	42
140	Understanding the Link between Dementia and Diabetes. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 389-392.	1.2	3
141	Diabetes and Alzheimer's Disease: Can Tea Phytochemicals Play a Role in Prevention?. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 481-501.	1.2	46
142	Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1293-1302.	1.2	35
143	Cognitive Function After Testosterone Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2335.	3.8	1
144	Lipidomic Profiles in Diabetes and Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 433-444.	1.2	49

#	ARTICLE	IF	CITATIONS
145	Intense resistance exercise increases peripheral brain-derived neurotrophic factor. <i>Journal of Science and Medicine in Sport</i> , 2017, 20, 899-903.	0.6	51
146	Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 193-201.	1.2	12
147	A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β 2-amyloid load in an AD cohort. <i>Scientific Reports</i> , 2017, 7, 14057.	1.6	22
148	Age-related neurodegenerative disease associated pathways identified in retinal and vitreous proteome from human glaucoma eyes. <i>Scientific Reports</i> , 2017, 7, 12685.	1.6	105
149	Impact of Cochlear Implantation on Cognitive Functions of Older Adults: Pilot Test Results. <i>Otology and Neurotology</i> , 2017, 38, e289-e295.	0.7	72
150	Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. <i>Scientific Reports</i> , 2017, 7, 9766.	1.6	59
151	BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF. <i>International Psychogeriatrics</i> , 2017, 29, 1825-1834.	0.6	21
152	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 169-183.	1.2	21
153	Study protocol of the Intense Physical Activity and Cognition study: The effect of high-intensity exercise training on cognitive function in older adults. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 562-570.	1.8	15
154	Amyloid β -associated cognitive decline in the absence of clinical disease progression and systemic illness. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 156-164.	1.2	19
155	Retinal vascular and structural changes are associated with amyloid burden in the elderly: ophthalmic biomarkers of preclinical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 13.	3.0	88
156	Multiple Mechanisms Linking Type 2 Diabetes and Alzheimer's Disease: Testosterone as a Modifier. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 445-466.	1.2	36
157	Associations of neighborhood environment with brain imaging outcomes in the Australian Imaging, Biomarkers and Lifestyle cohort. <i>Alzheimer's and Dementia</i> , 2017, 13, 388-398.	0.4	23
158	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. <i>Alzheimer's and Dementia</i> , 2017, 13, 45-58.	0.4	227
159	Plasma Cortisol, Brain Amyloid- β , and Cognitive Decline in Preclinical Alzheimer's Disease: A 6-Year Prospective Cohort Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2017, 2, 45-52.	1.1	32
160	[P3-202]: LEVEL OF P3-ALC β PEPTIDES ALTER IN CSF OF AD PATIENTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1013.	0.4	0
161	[P3-243]: A MASS SPECTROMETRY-BASED DISCOVERY AND REPLICATION OF A MULTI-ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1033.	0.4	0
162	[P4-136]: IL-10 AND IL-12/23P40 ARE JOINTLY ASSOCIATED AS PREDICTORS OF β -AMYLOID LOAD IN A BROADER BLOOD-BASED BIOMARKER PANEL. <i>Alzheimer's and Dementia</i> , 2017, 13, P1308.	0.4	0

#	ARTICLE	IF	CITATIONS
163	Evaluation of Cholinergic Deficiency in Preclinical Alzheimer's Disease Using Pupillometry. Journal of Ophthalmology, 2017, 2017, 1-8.	0.6	29
164	Modulation of Retinal Arteriolar Central Reflection by APOE Genotype. Current Alzheimer Research, 2017, 14, 916-923.	0.7	8
165	Possible role of common spices as a preventive and therapeutic agent for Alzheimer's disease. International Journal of Preventive Medicine, 2017, 8, 5.	0.2	29
166	Subjective Memory Complaints in APOE ε4 Carriers are Associated with High Amyloid-β Burden. Journal of Alzheimer's Disease, 2016, 49, 1115-1122.	1.2	45
167	Diet and Inflammation in Alzheimer's Disease and Related Chronic Diseases: A Review. Journal of Alzheimer's Disease, 2016, 50, 301-334.	1.2	46
168	The Effects of Testosterone Supplementation on Cognitive Functioning in Older Men.. CNS and Neurological Disorders - Drug Targets, 2016, 15, 337-343.	0.8	56
169	Cerebral Glucose Metabolism is Associated with Verbal but not Visual Memory Performance in Community-Dwelling Older Adults. Journal of Alzheimer's Disease, 2016, 52, 661-672.	1.2	23
170	P3-186: Moderate Consumption of Alcohol Modifies The Risk of Alzheimer's Disease and is Associated with Lower Levels of Cortisol. Alzheimer's and Dementia, 2016, 12, P892.	0.4	0
171	P2-020: Targeting Preclinical Stages of Alzheimer's Disease: A Clinical Trial to Assess The Efficacy Of Curcumin Using Brain Biomarkers. Alzheimer's and Dementia, 2016, 12, P616.	0.4	0
172	The Effects of Latrepirdine on Amyloid-β Aggregation and Toxicity. Journal of Alzheimer's Disease, 2016, 50, 895-905.	1.2	10
173	P1-300: Cost Effective AB Enrichment Strategies for Recruiting a Preclinical Cohort. , 2016, 12, P536-P536.		0
174	P3-303: Effects of ab and Bdnf Val66Met on Episodic Memory, Hippocampal Volume and Serum BDNF in Preclinical Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P957.	0.4	0
175	S4-01-03: Correlation of Plasma Proteomic Biomarkers with Cerebral Amyloid in the Aibl Longitudinal Study of Aging. Alzheimer's and Dementia, 2016, 12, P321.	0.4	0
176	IC-P-024: PIB Pet Centiloid Quantification Using Capaibl. , 2016, 12, P26-P27.		0
177	IC-P-049: Cost Effective Aβ Enrichment Strategies For Recruiting A Preclinical Cohort. Alzheimer's and Dementia, 2016, 12, P40.	0.4	0
178	IC-P-062: Effects of Mapt Over Brain Grey Matter Atrophy in The Aibl Cohort. Alzheimer's and Dementia, 2016, 12, P50.	0.4	0
179	IC-P-064: Regional Association Between Cortical Volumes and Imaging TAU Pathology Using ¹⁸ F-AV1451 and ¹⁸ F-THK5351. Alzheimer's and Dementia, 2016, 12, P51.	0.4	0
180	P1-299: Antihypertensive Treatment and Longitudinal Aβ Measures: Results from The AIBL Study of Ageing. , 2016, 12, P535-P536.		0

#	ARTICLE	IF	CITATIONS
181	P1-351: A β Related Memory Decline and Hippocampal Volume Loss in Mild Cognitive Impairment. , 2016, 12, P564-P564.		0
182	P2-240: Effects of Mapt over Brain Grey Matter Atrophy in the AIBL Cohort. Alzheimer's and Dementia, 2016, 12, P716.	0.4	0
183	P2-326: Difference in the Rate of Cognitive Change between Individuals with and Without Vascular Risk Factors: A Longitudinal Study. , 2016, 12, P766-P767.		0
184	P3-154: Plasma Biomarkers of Neocortical Amyloid Burden: An in-Depth Plasma Profile Using LC-MS. Alzheimer's and Dementia, 2016, 12, P878.	0.4	0
185	P4-182: PIB-PET Centiloid Quantification Using Capabl. , 2016, 12, P1089-P1090.		0
186	O2-03-05: Cerebrovascular Disease, Alzheimer's Disease Biomarkers and Longitudinal Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P228.	0.4	0
187	O2-04-02: Age Increases Rate of ab- and E4-Related Memory Decline in Preclinical Alzheimer's Disease. , 2016, 12, P229-P230.		0
188	O3-02-03: Regional Association between Cortical Volumes and Imaging Tau Pathology Using 18 F-AV1451 And 18 F-THK5351. , 2016, 12, P283-P283.		0
189	O4-05-02: Dietary Fibre and Protein Intake and Associations with Blood and Brain Amyloid Beta Burden in Healthy Individuals. , 2016, 12, P342-P342.		0
190	O4-06-01: Mesial Temporal Tau Burden in Older Adults with Subjective Memory Complaints Relates to Poorer Memory Function. , 2016, 12, P344-P345.		2
191	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network. , 2016, 12, P378-P379.		0
192	A β -related memory decline in APOE ϵ 4 noncarriers. Neurology, 2016, 86, 1635-1642.	1.5	37
193	Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults. British Journal of Nutrition, 2016, 115, 2106-2113.	1.2	147
194	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 27-34.	1.2	44
195	sFRP-mediated Wnt sequestration as a potential therapeutic target for Alzheimer's disease. International Journal of Biochemistry and Cell Biology, 2016, 75, 104-111.	1.2	14
196	β -Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men. American Journal of Geriatric Psychiatry, 2016, 24, 1191-1195.	0.6	25
197	Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia. Journal of Molecular Neuroscience, 2016, 60, 362-370.	1.1	14
198	Predicting Alzheimer disease from a blood-based biomarker profile. Neurology, 2016, 87, 1093-1101.	1.5	26

#	ARTICLE	IF	CITATIONS
199	Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. <i>Lancet Neurology</i> , The, 2016, 15, 1044-1053.	4.9	175
200	Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 29078.	1.6	39
201	P3-308: PLASMA CORTISOL, AMYLOID-B, and Cognitive Decline in Preclinical Alzheimer's Disease. , 2016, 12, P960-P960.		0
202	Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). <i>Lancet Neurology</i> , The, 2016, 15, 1317-1325.	4.9	87
203	Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 887-894.	1.2	40
204	The Relationship between Sleep Quality and Brain Amyloid Burden. <i>Sleep</i> , 2016, 39, 1063-1068.	0.6	123
205	Exploring the bi-directional relationship between sleep and beta-amyloid. <i>Current Opinion in Psychiatry</i> , 2016, 29, 397-401.	3.1	28
206	Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 19-26.	1.2	72
207	Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 18-26.	1.2	30
208	One protein, multiple pathologies: multifaceted involvement of amyloid β^2 in neurodegenerative disorders of the brain and retina. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 4279-4297.	2.4	60
209	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. <i>Annals of Neurology</i> , 2016, 79, 929-939.	2.8	381
210	Validation and Characterization of a Novel Peptide That Binds Monomeric and Aggregated β^2 -Amyloid and Inhibits the Formation of Neurotoxic Oligomers. <i>Journal of Biological Chemistry</i> , 2016, 291, 547-559.	1.6	15
211	Cerebral amyloid- β^2 accumulation and deposition following traumatic brain injury—A narrative review and meta-analysis of animal studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 64, 215-228.	2.9	34
212	Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 796-804.	0.4	135
213	Increased dementia risk following androgen deprivation therapy?. <i>Nature Reviews Urology</i> , 2016, 13, 188-189.	1.9	4
214	Lead and manganese levels in serum and erythrocytes in Alzheimer's disease and mild cognitive impairment: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. <i>Metallomics</i> , 2016, 8, 628-632.	1.0	30
215	High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2016, 13, 787-799.	0.7	23
216	Alzheimer's Disease and the Early Signs of Age-Related Macular Degeneration. <i>Current Alzheimer Research</i> , 2016, 13, 1259-1266.	0.7	42

#	ARTICLE	IF	CITATIONS
217	Comparative analysis of the Cancer Council of Victoria and the online Commonwealth Scientific and Industrial Research Organisation FFQ. <i>British Journal of Nutrition</i> , 2015, 114, 1683-1693.	1.2	5
218	O1-11-02: In vivo evaluation of the therapeutic potential of novel translocator protein (TSPO) ligands for the treatment of Alzheimer's disease. , 2015, 11, P156-P157.		0
219	O4-06-04: Mediterranean diet adherence is associated with less cerebral amyloid accumulation over time: Data from the australian imaging, biomarkers, and lifestyle study of ageing. , 2015, 11, P281-P282.		0
220	IC-P-170: Interaction between 18 F-THK5317, 18 F-flutemetamol SUVR and cortical thickness. , 2015, 11, P113-P113.		0
221	IC-P-169: BDNF, A β 2, and cortical atrophy in preclinical Alzheimer's disease. , 2015, 11, P112-P113.		0
222	Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease.. <i>Neuropsychology</i> , 2015, 29, 571-581.	1.0	43
223	Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in β -PET Amyloid- β 2 Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 175-187.	1.2	47
224	Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 443-452.	1.2	7
225	Alterations in dorsal and ventral posterior cingulate connectivity in APOE ϵ 4 carriers at risk of Alzheimer's disease. <i>BJPsych Open</i> , 2015, 1, 139-148.	0.3	5
226	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 1079-1089.	1.2	28
227	Alzheimer's disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 71.	3.0	14
228	A depressive endophenotype of poorer cognition among cognitively healthy community-dwelling adults: results from the Western Australia memory study. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 881-886.	1.3	9
229	Bone mineral density, adiposity, and cognitive functions. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 16.	1.7	23
230	Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ϵ 4 and Is Detectable over 18-Months. <i>PLoS ONE</i> , 2015, 10, e0139082.	1.1	22
231	Diagnostic Value of Subjective Memory Complaints Assessed with a Single Item in Dominantly Inherited Alzheimer's Disease: Results of the DIAN Study. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	7
232	Inflammation and Oxidative Stress: The Molecular Connectivity between Insulin Resistance, Obesity, and Alzheimer's Disease. <i>Mediators of Inflammation</i> , 2015, 2015, 1-17.	1.4	360
233	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015, 11, 549-560.	0.4	205
234	O3-03-04: Characteristics of the neighborhood built environment are associated with MRI brain volumetric and amyloid beta burden measures: Findings from the australian imaging, biomarkers, and lifestyle (AIBL) study. , 2015, 11, P223-P225.		0

#	ARTICLE	IF	CITATIONS
235	Bayesian Graphical Network Analyses Reveal Complex Biological Interactions Specific to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 917-925.	1.2	13
236	APOE ϵ 4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1239-1244.	1.5	75
237	Comparison of MR-less PiB SUVR quantification methods. <i>Neurobiology of Aging</i> , 2015, 36, S159-S166.	1.5	96
238	Relationships Between Performance on the Cogstate Brief Battery, Neurodegeneration, and A β Accumulation in Cognitively Normal Older Adults and Adults with MCI. <i>Archives of Clinical Neuropsychology</i> , 2015, 30, 49-58.	0.3	40
239	The impact of luteinizing hormone and testosterone on beta amyloid (A β) accumulation: Animal and human clinical studies. <i>Hormones and Behavior</i> , 2015, 76, 81-90.	1.0	25
240	Zinc affects the proteolytic stability of Apolipoprotein E in an isoform-dependent way. <i>Neurobiology of Disease</i> , 2015, 81, 38-48.	2.1	16
241	Longitudinal cognitive decline in the AIBL cohort: The role of APOE ϵ 4 status. <i>Neuropsychologia</i> , 2015, 75, 411-419.	0.7	27
242	Alzheimer's disease-related peptide PS2V plays ancient, conserved roles in suppression of the unfolded protein response under hypoxia and stimulation of β -secretase activity. <i>Human Molecular Genetics</i> , 2015, 24, 3662-3678.	1.4	33
243	The role of type 2 diabetes in neurodegeneration. <i>Neurobiology of Disease</i> , 2015, 84, 22-38.	2.1	209
244	Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. <i>Neurobiology of Aging</i> , 2015, 36, 1231-1238.	1.5	71
245	Amyloid- β , Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease. <i>JAMA Psychiatry</i> , 2015, 72, 284.	6.0	160
246	APOE ϵ 4 moderates abnormal CSF- β 42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals – a cross-sectional observational study. <i>BMC Neurology</i> , 2015, 15, 51.	0.8	46
247	Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 16.	3.0	22
248	First Demonstration of Positive Allosteric-like Modulation at the Human Wild Type Translocator Protein (TSPO). <i>Journal of Medicinal Chemistry</i> , 2015, 58, 8743-8749.	2.9	12
249	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2015, 85, 790-798.	1.5	27
250	Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment. <i>Age and Ageing</i> , 2015, 44, 1012-1019.	0.7	31
251	Innovative diagnostic tools for early detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 561-578.	0.4	213
252	Decreased Platelet APP Isoform Ratios in Autosomal Dominant Alzheimer's Disease: Baseline Data from a DIAN Cohort Subset. <i>Current Alzheimer Research</i> , 2015, 12, 157-164.	0.7	10

#	ARTICLE	IF	CITATIONS
253	Buccal Cell Cytokeratin 14 Identifies Mild Cognitive Impairment and Alzheimer's Disease in the AIBL Study of Aging. <i>Current Alzheimer Research</i> , 2015, 12, 233-241.	0.7	11
254	Testosterone Replacement Therapy in Older Male Subjective Memory Complainers: Double-Blind Randomized Crossover Placebo-Controlled Clinical Trial of Physiological Assessment and Safety. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 576-586.	0.8	18
255	Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer's Disease: A Preliminary Study. <i>PLoS ONE</i> , 2014, 9, e86498.	1.1	75
256	Biomarkers of Alzheimer's Disease Risk in Peripheral Tissues; Focus on Buccal Cells. <i>Current Alzheimer Research</i> , 2014, 11, 519-531.	0.7	31
257	Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study. <i>British Journal of Psychiatry</i> , 2014, 204, 400-401.	1.7	29
258	Hypoxia alters expression of Zebrafish Microtubule-associated protein Tau (mapta, maptb) gene transcripts. <i>BMC Research Notes</i> , 2014, 7, 767.	0.6	14
259	Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments – an update for clinicians. <i>Neurodegenerative Disease Management</i> , 2014, 4, 363-378.	1.2	20
260	Altered cytological parameters in buccal cells from individuals with mild cognitive impairment and Alzheimer's disease. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2014, 85, 698-708.	1.1	31
261	Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease. <i>Science Translational Medicine</i> , 2014, 6, 226ra30.	5.8	320
262	Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). <i>International Psychogeriatrics</i> , 2014, 26, 543-554.	0.6	37
263	Incidence of cerebral microbleeds in preclinical Alzheimer disease. <i>Neurology</i> , 2014, 82, 1266-1273.	1.5	125
264	Testosterone as the Missing Link Between Pesticides, Alzheimer Disease, and Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 1189.	4.5	3
265	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1111.	4.5	112
266	Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults. <i>International Psychogeriatrics</i> , 2014, 26, 1737-1746.	0.6	9
267	The Involvement of Lipids in Alzheimer's Disease. <i>Journal of Genetics and Genomics</i> , 2014, 41, 261-274.	1.7	55
268	Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. <i>Brain</i> , 2014, 137, 221-231.	3.7	182
269	Ageing, cortical injury and Alzheimer's disease-like pathology in the guinea pig brain. <i>Neurobiology of Aging</i> , 2014, 35, 1345-1351.	1.5	23
270	Differential, dominant activation and inhibition of Notch signalling and APP cleavage by truncations of PSEN1 in human disease. <i>Human Molecular Genetics</i> , 2014, 23, 602-617.	1.4	48

#	ARTICLE	IF	CITATIONS
271	Decreased serum zinc is an effect of ageing and not Alzheimer's disease. <i>Metallomics</i> , 2014, 6, 1216-1219.	1.0	34
272	Influence of <i>BDNF</i> Val66Met on the relationship between physical activity and brain volume. <i>Neurology</i> , 2014, 83, 1345-1352.	1.5	58
273	Among Vitamin B12 Deficient Older People, High Folate Levels are Associated with Worse Cognitive Function: Combined Data from Three Cohorts. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 661-668.	1.2	76
274	Symptom onset in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2014, 83, 253-260.	1.5	391
275	A β and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 743.	0.4	66
276	An increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation. <i>Journal of Neuroimmunology</i> , 2014, 273, 65-71.	1.1	87
277	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 53-61.	0.4	114
278	Plasma Amyloid- β Levels are Significantly Associated with a Transition Toward Alzheimer's Disease as Measured by Cognitive Decline and Change in Neocortical Amyloid Burden. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 95-104.	1.2	41
279	Amyloid- β Related Memory Decline is not Associated with Subjective or Informant Rated Cognitive Impairment in Healthy Adults. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 677-686.	1.2	63
280	Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease. <i>BMC Bioinformatics</i> , 2014, 15, S11.	1.2	67
281	Is Cholesterol and Amyloid- β Stress Induced CD147 Expression a Protective Response? Evidence that Extracellular Cyclophilin A Mediated Neuroprotection is Reliant on CD147. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 545-556.	1.2	11
282	Personal Memory Function in Mild Cognitive Impairment and Subjective Memory Complaints: Results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 551-561.	1.2	10
283	F5-02-03: PLASMA-BASED PROTEIN BIOMARKER PANEL FOR ALZHEIMER'S DISEASE: LONGITUDINAL DATA FROM AUSTRALIAN IMAGING BIOMARKERS AND LIFESTYLE STUDY OF AGING. , 2014, 10, P283-P284.		0
284	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4502-9.	3.3	309
285	Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. <i>Diabetes Care</i> , 2013, 36, 2981-2987.	4.3	308
286	Predicting Alzheimer disease with β -amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. <i>Annals of Neurology</i> , 2013, 74, 905-913.	2.8	194
287	Multiplex biomarkers in blood. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 31.	3.0	33
288	Longitudinal Analysis of Serum Copper and Ceruloplasmin in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 171-182.	1.2	46

#	ARTICLE	IF	CITATIONS
289	A β amyloid, cognition, and APOE genotype in healthy older adults. <i>Alzheimer's and Dementia</i> , 2013, 9, 538-545.	0.4	51
290	Research and standardization in Alzheimer's trials: Reaching international consensus. , 2013, 9, 160-168.		20
291	Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 357-367.	4.9	1,738
292	BDNF Val66Met, A β amyloid, and cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2457-2464.	1.5	109
293	Cross-sectional and Longitudinal Analysis of the Relationship Between A β Deposition, Cortical Thickness, and Memory in Cognitively Unimpaired Individuals and in Alzheimer Disease. <i>JAMA Neurology</i> , 2013, 70, 903.	4.5	170
294	Decline in Cognitive Function over 18 Months in Healthy Older Adults with High Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2013, 34, 861-871.	1.2	42
295	Lack of reliable evidence for a distinctive β 4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study. <i>Brain</i> , 2013, 136, 2201-2216.	3.7	28
296	Three-Month Stability of the CogState Brief Battery in Healthy Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease: Results from the Australian Imaging, Biomarkers, and Lifestyle-Rate of Change Substudy (AIBL-ROCS). <i>Archives of Clinical Neuropsychology</i> , 2013, 28, 320-330.	0.3	90
297	The association of A β amyloid and composite cognitive measures in healthy older adults and MCI. <i>International Psychogeriatrics</i> , 2013, 25, 1667-1677.	0.6	24
298	Cognitive Decline in Adults with Amnesic Mild Cognitive Impairment and High Amyloid- β : Prodromal Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 1167-1176.	1.2	34
299	Cognitive consequences of high A β amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer's disease.. <i>Neuropsychology</i> , 2013, 27, 322-332.	1.0	33
300	Biomarkers of Alzheimer's Disease Among Mexican Americans. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 841-849.	1.2	69
301	Rapid Decline in Episodic Memory in Healthy Older Adults with High Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2013, 33, 675-679.	1.2	62
302	Pupil Response Biomarkers Distinguish Amyloid Precursor Protein Mutation Carriers from Non-Carriers. <i>Current Alzheimer Research</i> , 2013, 10, 790-796.	0.7	30
303	Pathology Associated with AAV Mediated Expression of Beta Amyloid or C100 in Adult Mouse Hippocampus and Cerebellum. <i>PLoS ONE</i> , 2013, 8, e59166.	1.1	8
304	The Guinea Pig as a Model for Sporadic Alzheimer's Disease (AD): The Impact of Cholesterol Intake on Expression of AD-Related Genes. <i>PLoS ONE</i> , 2013, 8, e66235.	1.1	42
305	Pupil Response Biomarkers for Early Detection and Monitoring of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2013, 10, 931-939.	0.7	26
306	Developing an international network for Alzheimer's research: the Dominantly Inherited Alzheimer Network. <i>Clinical Investigation</i> , 2012, 2, 975-984.	0.0	180

#	ARTICLE	IF	CITATIONS
307	Regional dynamics of amyloid- β^2 deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. <i>Brain</i> , 2012, 135, 2126-2139.	3.7	222
308	Conference Scene: Dementia: bench-top research through to early diagnosis, interventions and clinical practice. <i>Neurodegenerative Disease Management</i> , 2012, 2, 361-364.	1.2	0
309	Lifestyle and late life cognitive health: sufficient evidence to act now?. <i>International Psychogeriatrics</i> , 2012, 24, 683-688.	0.6	2
310	Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. <i>International Psychogeriatrics</i> , 2012, 24, 197-204.	0.6	39
311	Stronger effect of amyloid load than <i>APOE</i> genotype on cognitive decline in healthy older adults. <i>Neurology</i> , 2012, 79, 1645-1652.	1.5	96
312	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 795-804.	13.9	3,005
313	Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 1318.	4.9	348
314	Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 345-358.	0.8	111
315	Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: The AIBL Active trial. <i>BMC Psychiatry</i> , 2012, 12, 167.	1.1	40
316	Latrepidine (Dimebon, Φ) Enhances Autophagy and Reduces Intracellular GFP-A β^2 Levels in Yeast. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 949-967.	1.2	68
317	Homocysteine, Vitamin B12, and Folic Acid Levels in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: Baseline Characteristics in Subjects of the Australian Imaging Biomarker Lifestyle Study. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 909-922.	1.2	83
318	Independent contribution of temporal β^2 -amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. <i>Brain</i> , 2011, 134, 798-807.	3.7	132
319	Zebrafish as a tool in Alzheimer's disease research. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 346-352.	1.8	60
320	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011, 7, 386.	0.4	354
321	The Dynamics of CD147 in Alzheimer's Disease Development and Pathology. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 593-605.	1.2	22
322	Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. <i>Neuropsychologia</i> , 2011, 49, 2384-2390.	0.7	139
323	New lexicon and criteria for the diagnosis of Alzheimer's disease. <i>Lancet Neurology</i> , The, 2011, 10, 299-300.	4.9	4
324	Longitudinal assessment of A β^2 and cognition in aging and Alzheimer disease. <i>Annals of Neurology</i> , 2011, 69, 181-192.	2.8	730

#	ARTICLE	IF	CITATIONS
325	Direct Exposure of Guinea Pig CNS to Human Luteinizing Hormone Increases Cerebrospinal Fluid and Cerebral Beta Amyloid Levels. <i>Neuroendocrinology</i> , 2011, 94, 313-322.	1.2	23
326	Relationship between atrophy and β -amyloid deposition in Alzheimer disease. <i>Annals of Neurology</i> , 2010, 67, 317-324.	2.8	322
327	Plasma Amyloid- β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1233-1242.	1.2	122
328	APOE Genotype Results in Differential Effects on the Peripheral Clearance of Amyloid- β 42 in APOE Knock-in and Knock-out Mice. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 403-409.	1.2	47
329	Profiling Brain and Plasma Lipids in Human APOE ϵ 2, ϵ 3, and ϵ 4 Knock-in Mice Using Electrospray Ionization Mass Spectrometry. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 105-111.	1.2	29
330	Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. <i>Neurobiology of Aging</i> , 2010, 31, 1503-1515.	1.5	179
331	Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. <i>Neurobiology of Aging</i> , 2010, 31, 1275-1283.	1.5	885
332	Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2010, 6, 291-296.	0.4	53
333	IC-01-03: Larger temporal volume in asymptomatic elderly with high versus low beta-amyloid deposition. , 2010, 6, S2-S3.		1
334	Ocular Biomarkers for Early Detection of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 1-16.	1.2	101
335	The Relationship Between Memory Complaints, Perceived Quality of Life and Mental Health in Apolipoprotein ϵ 4 Carriers and Non-Carriers. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 69-79.	1.2	25
336	Association of Cardiovascular Factors and Alzheimer's Disease Plasma Amyloid- β Protein in Subjective Memory Complainers. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 305-318.	1.2	26
337	The role of gonadotropins and testosterone in the regulation of beta-amyloid metabolism. , 2009, , 259-268.		0
338	Alcadin Cleavages by Amyloid β -Precursor Protein (APP) ϵ 2- and ϵ 3-Secretases Generate Small Peptides, p3-Alcs, Indicating Alzheimer Disease-related β -Secretase Dysfunction. <i>Journal of Biological Chemistry</i> , 2009, 284, 36024-36033.	1.6	46
339	Independent and cooperative action of Psen2 with Psen1 in zebrafish embryos. <i>Experimental Cell Research</i> , 2009, 315, 2791-2801.	1.2	47
340	β aggregation and possible implications in Alzheimer's disease pathogenesis. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 412-421.	1.6	129
341	Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2009, 111, 1275-1308.	2.1	211
342	The structure and function of Alzheimer's gamma secretase enzyme complex. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2009, 46, 282-301.	2.7	59

#	ARTICLE	IF	CITATIONS
343	Androgens and Alzheimer's disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 254-259.	1.2	29
344	Complex Splicing and Neural Expression of Duplicated Tau Genes in Zebrafish Embryos. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 305-317.	1.2	46
345	The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. <i>International Psychogeriatrics</i> , 2009, 21, 672-687.	0.6	661
346	Olfactory Dysfunction is Associated with Subjective Memory Complaints in Community-Dwelling Elderly Individuals. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 135-142.	1.2	39
347	Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 1463-1470.	6.6	288
348	Interference with splicing of Presenilin transcripts has potent dominant negative effects on Presenilin activity. <i>Human Molecular Genetics</i> , 2008, 17, 402-412.	1.4	48
349	Fluoro-2-Deoxy-D-Glucose (FDG)-PET in APOE ϵ 4 Carriers in the Australian Population. <i>Journal of Alzheimer's Disease</i> , 2008, 13, 137-146.	1.2	28
350	Gonadotropins and Cognition in Older Women. <i>Journal of Alzheimer's Disease</i> , 2008, 13, 267-274.	1.2	51
351	Luteinizing Hormone Levels Are Positively Correlated with Plasma Amyloid- β 2 Protein Levels in Elderly Men. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 201-208.	1.2	44
352	Distinct Effects of Testosterone on Plasma and Cerebrospinal Fluid Amyloid- β 2 Levels. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 129-137.	1.2	29
353	Chronic Inflammation and Amyloidogenesis in Alzheimer's Disease: The Emerging Role of Infection. <i>Journal of Alzheimer's Disease</i> , 2008, 13, 357-357.	1.2	3
354	Androgens in the Etiology of Alzheimer's Disease in Aging Men and Possible Therapeutic Interventions. <i>Journal of Alzheimer's Disease</i> , 2007, 12, 129-142.	1.2	51
355	Oxidative stress in a rat model of chronic gliosis. <i>Neurobiology of Aging</i> , 2007, 28, 995-1008.	1.5	14
356	The Role of Presenilin and its Interacting Proteins in the Biogenesis of Alzheimer's Beta Amyloid. <i>Neurochemical Research</i> , 2007, 32, 609-623.	1.6	49
357	The Role of Gonadotropins in Alzheimer's Disease: Potential Neurodegenerative Mechanisms. <i>Endocrine</i> , 2006, 29, 257-270.	2.2	28
358	Interaction between Testosterone and Apolipoprotein E ϵ 4 Status on Cognition in Healthy Older Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1168-1172.	1.8	55
359	Reproductive Hormones Modulate Oxidative Stress in Alzheimer's Disease. <i>Antioxidants and Redox Signaling</i> , 2006, 8, 2047-2059.	2.5	45
360	Plasma A β 242 correlates positively with increased body fat in healthy individuals. <i>Journal of Alzheimer's Disease</i> , 2005, 8, 269-282.	1.2	73

#	ARTICLE	IF	CITATIONS
361	The Significance of Age-Related Androgen Depletion in Cognitive Impairment: A Review. <i>Brain Impairment</i> , 2004, 5, 166-176.	0.5	0
362	Luteinizing Hormone, a Reproductive Regulator That Modulates the Processing of Amyloid- β Precursor Protein and Amyloid- β Deposition. <i>Journal of Biological Chemistry</i> , 2004, 279, 20539-20545.	1.6	154
363	Aging, gender and APOE isotype modulate metabolism of Alzheimer's A β peptides and F $_2$ -isoprostanes in the absence of detectable amyloid deposits. <i>Journal of Neurochemistry</i> , 2004, 90, 1011-1018.	2.1	40
364	One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. <i>Psychoneuroendocrinology</i> , 2004, 29, 1071-1081.	1.3	241
365	The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?. <i>Pharmacological Research</i> , 2004, 50, 397-409.	3.1	153
366	Alzheimer amyloid precursor aspartyl proteinase activity in CHAPSO homogenates of <i>Spodoptera frugiperda</i> cells. <i>Alzheimer Disease and Associated Disorders</i> , 2004, 18, 261-3.	0.6	4
367	Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease. <i>Biological Psychiatry</i> , 2003, 54, 136-141.	0.7	51
368	Molecular and Cellular Basis for Anti-Amyloid Therapy in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2003, 17, 259-266.	0.6	42
369	Alzheimer's β -Amyloid Peptides Compete for Insulin Binding to the Insulin Receptor. <i>Journal of Neuroscience</i> , 2002, 22, RC221-RC221.	1.7	290
370	Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. <i>Journal of Neuroscience Research</i> , 2002, 70, 514-518.	1.3	122
371	Amyloid β protein precursor metabolism as a modulator of islet β -cell function. <i>Journal of Alzheimer's Disease</i> , 2001, 3, 397-399.	1.2	3
372	The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid- β Levels: Resolubilization of amyloid- β with transition metal ion chelators. <i>Journal of Alzheimer's Disease</i> , 2001, 3, 209-219.	1.2	44
373	Effect of testosterone deprivation on the cognitive performance of a patient with Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 823-825.	1.3	11
374	Clinical characteristics of individuals with subjective memory loss in Western Australia: results from a cross-sectional survey. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 168-174.	1.3	126
375	Insulin Effects on Glucose Metabolism, Memory, and Plasma Amyloid Precursor Protein in Alzheimer's Disease Differ According to Apolipoprotein-E Genotype. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 222-228.	1.8	175
376	Inhibiting Amyloid Precursor Protein C-terminal Cleavage Promotes an Interaction with Presenilin 1. <i>Journal of Biological Chemistry</i> , 2000, 275, 20794-20798.	1.6	36
377	Effects of the amyloid protein precursor of Alzheimer's disease and other ligands of the LDL receptor-related protein on neurite outgrowth from sympathetic neurons in culture. <i>FEBS Letters</i> , 1998, 428, 13-16.	1.3	28
378	Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. <i>Neuroscience Letters</i> , 1997, 223, 29-32.	1.0	103

#	ARTICLE	IF	CITATIONS
379	Characterization of the Binding of Amyloid β Peptide to Cell Culture-Derived Native Apolipoprotein E2, E3, and E4 Isoforms and to Isoforms from Human Plasma. <i>Journal of Neurochemistry</i> , 1997, 68, 721-725.	2.1	98
380	Altered oxidation and signal transduction systems in fibroblasts from Alzheimer patients. <i>Life Sciences</i> , 1996, 59, 477-489.	2.0	59
381	ApoE genotypes in Australia. <i>NeuroReport</i> , 1995, 6, 1513-1516.	0.6	106
382	The Role of PDGF-BB on the Development of the Collateral Circulation after Acute Arterial Occlusion. <i>Growth Factors</i> , 1994, 10, 299-306.	0.5	34
383	Increased Cerebral Glucose-6-Phosphate Dehydrogenase Activity in Alzheimer's Disease May Reflect Oxidative Stress. <i>Journal of Neurochemistry</i> , 1986, 46, 1042-1045.	2.1	224
384	CSF Biomarkers in Down Syndrome and Autosomal Dominant Alzheimer Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
385	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 0, , .	0.4	2
386	Association of Plasma Neurofilament Light Chain With Glycaemic Control and Insulin Resistance in Middle-Aged Adults. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6
387	Comparison of Auditory Steady-State Responses With Conventional Audiometry in Older Adults. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	3